文献速递新发突发、热带与寄生虫病

化学预防疫苗接种:探索美国成人对恶性疟原虫阶段特异性免疫的I期研究

Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults.
PubMed 文献 · Clin Infect Dis · 2020-01-01

这项I期随机部分双盲安慰剂对照研究纳入36名无疟疾成人,评估以伯氨喹和/或氯喹为配伍药物的化学预防接种方案。结果显示CVac-伯氨喹/氯喹方案安全,并在部分受种者中诱导对恶性疟原虫的无菌免疫;CVac-氯喹方案未产生无菌免疫。

要点

  • CVac-伯氨喹/氯喹方案安全,部分受种者获得无菌免疫。
  • CVac-氯喹方案可使虫血症延迟但未产生无菌保护。
  • 暴露后单剂45 mg伯氨喹不能完全预防血期原虫血症。

核心结论

  • CVac-伯氨喹/氯喹方案安全,并在部分受种者中诱导对恶性疟原虫的无菌免疫。
  • 暴露后单剂45 mg伯氨喹不能完全预防血期原虫血症。
  • 与既往研究不同,CVac-氯喹方案未产生无菌免疫。

研究设计与样本

  • I期随机部分双盲安慰剂对照研究,纳入36名无疟疾成人。
  • CVac受种者接受氯喹预防并每月接受12-15只感染恶性疟原虫蚊虫叮咬,共3次;部分受种者暴露后接受伯氨喹。
  • 药物对照接受伯氨喹、氯喹及未感染蚊虫叮咬。
  • 氯喹洗脱后,受试者(包括未经治疗的感染对照)接受同源PfSPZ控制性人疟感染,监测原虫血症21天。

主要发现

  • 未发生严重不良事件。
  • CVac期间,除1名受试者外所有受试者血涂片保持阴性;仅1名受试者(伯氨喹/氯喹组)聚合酶链反应保持阴性。
  • 攻击后,与感染对照相比,氯喹组3/3受试者出现延迟的可见原虫血症(P = .01),但无无菌保护。
  • 伯氨喹/氯喹组3/11受试者血涂片保持阴性。

关键数值与推荐

  • CVac-氯喹组攻击后可见原虫血症延迟,P = .01。
  • 伯氨喹/氯喹组3/11受试者攻击后血涂片阴性。
  • 暴露后单剂伯氨喹45 mg未能完全预防血期原虫血症。

临床怎么用

  • CVac-伯氨喹/氯喹方案在部分受种者中诱导无菌免疫,支持进一步研究其保护机制。
  • 暴露后单剂45 mg伯氨喹不足以完全清除血期原虫,需评估剂量或方案优化。
  • CVac-氯喹方案未产生无菌免疫,提示血期暴露可能影响保护效果。

局限性

  • 样本量较小(36名成人),结果需更大规模研究验证。
  • 研究为I期探索性设计,部分双盲,可能影响偏倚控制。
  • 攻击使用同源PfSPZ,未评估异源保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemoprophylaxis vaccination with sporozoites (CVac) with chloroquine induces protection against a homologous Plasmodium falciparum sporozoite (PfSPZ) challenge, but whether blood-stage parasite exposure is required for protection remains unclear. Chloroquine suppresses and clears blood-stage parasitemia, while other antimalarial drugs, such as primaquine, act against liver-stage parasites. Here, we evaluated CVac regimens using primaquine and/or chloroquine as the partner drug to discern whether blood-stage parasite exposure impacts protection against homologous controlled human malaria infection. METHODS: In a Phase I, randomized, partial double-blind, placebo-controlled study of 36 malaria-naive adults, all CVac subjects received chloroquine prophylaxis and bites from 12-15 P. falciparum-infected mosquitoes (CVac-chloroquine arm) at 3 monthly iterations, and some received postexposure primaquine (CVac-primaquine/chloroquine arm). Drug control subjects received primaquine, chloroquine, and uninfected mosquito bites. After a chloroquine washout, subjects, including treatment-naive infectivity controls, underwent homologous, PfSPZ controlled human malaria infection and were monitored for parasitemia for 21 days. RESULTS: No serious adverse events occurred. During CVac, all but 1 subject in the study remained blood-smear negative, while only 1 subject (primaquine/chloroquine arm) remained polymerase chain reaction-negative. Upon challenge, compared to infectivity controls, 3/3 chloroquine arm subjects displayed delayed patent parasitemia (P = .01) but not sterile protection, while 3/11 primaquine/chloroquine subjects remained blood-smear negative. CONCLUSIONS: CVac-primaquine/chloroquine is safe and induces sterile immunity to P. falciparum in some recipients, but a single 45 mg dose of primaquine postexposure does not completely prevent blood-stage parasitemia. Unlike previous studies, CVac-chloroquine did not produce sterile immunity. CLINICAL TRIALS REGISTRATION: NCT01500980.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Healy SA, Murphy SC, Hume JCC, et al. Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults. Clin Infect Dis. 2020. PMID: 31621832. doi:10.1093/cid/ciz1010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。